A final-stage clinical trial comparing a new long-acting, once-weekly pill to treat schizophrenia symptoms with the existing daily treatment has found that both produce comparable therapeutic effects.

LYN-005 is an investigational long-acting oral capsule formulation of the atypical antipsychotic risperidone. Positive data were announced from a phase 3 study comparing the pharmacokinetic (PK) ...

Risperidone 0.5mg, 1mg, 2mg, 3mg, 4mg; contains phenylalanine. Initially 2–3mg once daily; may adjust at intervals of at least 24hrs by 1mg/day. Usual range: 1–6mg/day; max 6mg/day. Elderly, ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

Patients with severe mental illnesses, such as schizophrenia and bipolar disorder, often require long-term use of ...